This report uses data extracted from every PrEP prescription supplied in Australia through the Pharmaceutical Benefits Scheme (PBS) between 1 April 2018 and 30 June 2022. Data are presented on the total number of people who have ever initiated PBS-subsidised PrEP, as well as the number of people dispensed PrEP within the past 12 months. These data are disaggregated by age, and by state or territory of patient residence.
The Australian COVID-19 Serosurveillance Network is conducting a series of regular serological surveys during 2022 among Australian blood donors (aged 18 years and over) to provide estimates of the proportion of the population that have SARS-CoV-2 antibodies (i.e., seroprevalence).
Following initial serosurveillance activities in 2020, the Australian COVID-19 Serosurveillance Network has embarked on a program of repeat surveys of blood donors. The program aims to estimate the prevalence of antibodies to SARS-CoV-2, whether derived from vaccination or natural infection and examine variations over time using repeat cross-sectional surveys of Australian blood donors.
This report uses data extracted from every PrEP prescription supplied in Australia through the Pharmaceutical Benefits Scheme (PBS) between 1 April 2018 and 31 December 2021. Data are presented on the total number of people who have ever initiated PBS-subsidised PrEP, as well as the number of people dispensed PrEP within the past 12 months. These data are disaggregated by age, and by state or territory of patient residence.
This report uses data extracted from every PrEP prescription supplied in Australia through the Pharmaceutical Benefits Scheme (PBS) between 1 April 2018 and 30 September 2021. Data are presented on the total number of people who have ever initiated PBS-subsidised PrEP, as well as the number of people dispensed PrEP within each quarter. These data are disaggregated by age, and by state or territory of patient residence.
The Needle Syringe Program National Minimum Data Collection (NSP NMDC) supports the National Strategies for blood borne and sexually transmissible infections and complements the annual Australian Needle Syringe Program Survey National Data Report.
This report uses data extracted from every PrEP prescription supplied in Australia through the Pharmaceutical Benefits Scheme (PBS) between 1 April 2018 and 31 March 2021. Data are presented on the total number of people who have ever initiated PBS-subsidised PrEP, as well as the number of people dispensed PrEP within each quarter. These data are disaggregated by age, and by state or territory of patient residence.
The Needle Syringe Program National Minimum Data Collection (NSP NMDC) supports the National Strategies for blood borne and sexually transmissible infections and complements the annual Australian Needle Syringe Program Survey National Data Report.
PBS-subsidised HIV pre-exposure prophylaxis from April 2018 to June 2020.
PBS-subsidised HIV pre-exposure prophylaxis from April 2018 to June 2019
